 I think that from the FDA perspective, the main thing that they are limited by is the resources in order to work on different programs like qualifying a new endpoint. So I think lawmakers can help provide the FDA the resources to do that because they're overworked. They have many, many things to do at the FDA, and their priority is the new drugs where there's a strict timeline on when they have to act.